MURFREESBORO, TN / ACCESS Newswire / February 7, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today that after more than 34 years of leadership and guidance on the NHI Board of ...
Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation. A first tranche of ...
Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.78% of subjects maintained a ...
CLEVELAND, OH / ACCESS Newswire / February 7, 2025 / Dr. Airica Steed's legacy as the CEO of MetroHealth is one defined by progress, innovation, and an unwavering commitment to creating a more ...
Dermaliq Therapeutics, Inc. (Dermaliq) today announces that Ralf Paus, M.D., D.Sc., F.R.S.B. has joined the company’s Scientific and Medical Advisory Board.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...